(Q50663112)

17 March 2018

title

[Interferon beta 1-a in multiple sclerosis: 1-year experience in 62 patients] (English)

1 reference

17 March 2018

0 references

Tilbery CP

1

1 reference

17 March 2018

Felipe E

2

1 reference

17 March 2018

Moreira MA

3

1 reference

17 March 2018

Mendes MF

4

1 reference

17 March 2018

França AS

5

1 reference

17 March 2018

publication date

1 June 2000

1 reference

17 March 2018

Arquivos de Neuro-Psiquiatria

published in

1 reference

17 March 2018

volume

58

1 reference

17 March 2018

issue

2B

1 reference

17 March 2018

page(s)

452-459

1 reference

17 March 2018

In vitro intercellular adhesion molecule-1 expression on brain endothelial cells in multiple sclerosis.

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2000000300009

Intrathecal Interferon Reduces Exacerbations of Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2000000300009

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2000000300009

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2000000300009

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2000000300009

Multiple sclerosis (first of two parts).

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2000000300009

Multiple sclerosis and viruses: An overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2000000300009

In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2000000300009

Interferon-beta specifically inhibits interferon-gamma-induced class II major histocompatibility complex gene transcription in a human astrocytoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2000000300009

T-cell recognition of myelin basic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2000000300009

Intrathecal interferon in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2000000300009

Clinical trials of interferons in multiple sclerosis. What have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2000000300009

Assessment of MRI criteria for a diagnosis of MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2000000300009

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2000000300009

Clinical scales for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2000000300009

Low-dose steroids reduce flu-like symptoms at the initiation of IFNbeta-1b in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2000000300009

Amelioration of flulike symptoms at the onset of interferon β- 1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2000000300009

Treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2000000300009

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2000000300009

10.1590/S0004-282X2000000300009

21 January 2018

Identifiers

DOI

1 reference

17 March 2018

PubMed ID

10920406

1 reference

17 March 2018